CER-1236 (novel investigational agent for AML/MDS/MF)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-27 — CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF): First-in-human Phase 1/1b open-label trial launched evaluating safety and preliminary efficacy of CER-1236 in relapsed/refractory or MRD-positive AML, MDS, and myelofibrosis, including TP53-mutated disease (trial-early). (novelty: 4)
Open questions
Related
Contributing findings
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
27-mar-2026
novelty 4
per-area 4
introduces